RxDoctor Payments Data

Milena Khorshid, MD

Internal Medicine · Bradenton, FLNPI 1235265349

Payments from drug & device makers

$3,045in general payments, 2019–2025

Across 161 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$555
  • Lilly USA, LLC$488
  • GSK$418
  • AbbVie$314
  • AstraZeneca$300
  • Amgen$193
  • plus $776 from 15 others

What the payments were for

  • Food & beverage$3,033100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,045 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$61,783
Medicare patients
150
Services billed
686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide236$291,382
OzempicSemaglutide105$129,037
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$105,720
JardianceEmpagliflozin65$97,126
EliquisApixaban56$70,017
XareltoRivaroxaban34$42,624
FarxigaDapagliflozin Propanediol33$33,346
MyrbetriqMirabegron15$23,670
JanuviaSitagliptin Phosphate16$19,295
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$7,016
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$6,958
Breo ElliptaFluticasone/Vilanterol13$6,752
SymbicortBudesonide/Formoterol Fumarate19$6,607
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$6,316
Gabapentin179$5,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$488$291,382236 claims
Novo NordiskOzempic$105$129,037105 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$418$118,788113 claims
Boehringer IngelheimJardiance, Stiolto Respimat$64$104,08480 claims
PfizerEliquis$146$70,01756 claims
AstraZenecaFarxiga, Symbicort$300$39,95352 claims
MerckJanuvia$15$19,29516 claims
AbbVieSynthroid$314$1,23317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →